Although APP metabolism is being intensively investigated, a large fraction of its modulators are yet to be characterized. In this context, we combined two genome-wide high-content screenings to assess the functional impact of miRNAs and genes on APP metabolism and the signaling pathways involved. This approach highlighted the involvement of FERMT2 (or Kindlin-2), a genetic risk factor of Alzheimer's disease (AD), as a potential key modulator of axon guidance; a neuronal process dependent on the APP metabolism regulation. We found that FERMT2 directly interacts with APP to modulate its metabolism and that FERMT2 under-expression impacts axonal growth, synaptic connectivity and long-term potentiation in an APP-dependent manner. Lastly, the rs7143400-T allele, which is associated with an increased AD risk and localized within the 3'UTR of FERMT2, induced a down-regulation of FERMT2 expression through binding of miR-4504. This miRNA is mainly expressed in neurons and significantly overexpressed in AD brains compared to controls. Altogether, our data provide strong evidence for a detrimental effect of FERMT2 under-expression in neurons and insight on how this may influence AD pathogenesis.
INTRODUCTION
AD is a neurodegenerative disease characterized by two main pathological hallmarks: (i) intracellular neurofibrillary tangles consisting of hyper-phosphorylated Tau proteins and (ii) extracellular amyloid plaques consisting of aggregates of β-amyloid (Aβ) peptides resulting from the processing of amyloid precursor protein (APP). Three main proteases (α-, β-and γsecretases) are involved in APP processing through (i) the amyloidogenic pathway (β-and γ-secretases), leading to Aβ production, and (ii) the non-amyloidogenic pathway (α-and γ -secretases), which prevents Aβ generation by cleaving APP within the Aβ sequence (Checler 1995) .
The identification of early-onset autosomal dominant AD-linked mutations in the genes for APP and presenilins (PS1 and PS2, part of the γ-secretase), but also late-onset sporadic AD-linked mutations in ADAM10 (carrying part of the α-secretase activity in the brain) (Kim et al. 2009 ), have placed abnormal APP metabolism at the center of the disease, further supporting the amyloid cascade hypothesis (Hardy 1997; Hardy & Selkoe 2002) : the overproduction of Aβ peptides -especially the longer forms that are thought to be more neurotoxic-may lead to (or favor) Tau pathology and subsequent neuronal death.
Although the validity of the amyloid cascade hypothesis is strongly debated (Morris et al. 2018) , the importance of APP has recently been emphasized by the discovery of a rare APP mutation hampering Aβ production that lowers AD risk (Jonsson et al. 2012) . Recent high-throughput genomic approaches have also highlighted APP metabolism in the AD pathophysiological process: the main actors of APP metabolism, e.g., ADAM10 and APH1B (part of the γ-secretase complex), have been characterized as genetic determinants (Jansen et al. 2019; Kunkle et al. 2019) , and numerous other genetic determinants have been described as potential modulators of APP metabolism (for a review, see (Dourlen et al. 2019) ). Taken together, these genetic data strongly suggest that APP metabolism regulation and consequently APP function still need to be better understood to decipher the AD pathophysiological processes.
Previously, we have used a high content screening (HCS) approach that allowed us to identify 832 genes able to strongly modify APP metabolism (Chapuis et al. 2017) . One can argue that endogenous mechanisms regulating the expression of such key players of APP metabolism may be also of importance in the development of the AD processes. Among the different mechanisms involved in gene regulation, microRNAs (miRNAs) appeared of particular interest for several reasons: (i) miRNAs are abundantly expressed in the brain and it is now well established that specific miRNAs expression is altered in AD brain (Hébert et al. 2008; Patrick et al. 2017 ), (ii) several of these miRNAs have been already implicated in APP metabolism (Delay et al. 2016; Z. Li et al. 2017; Long et al. 2019 ); (iii) miRNAs have been implicated in various neuronal functions including synaptic plasticity, memory formation and neuron survival which are relevant in the AD context (Schratt 2009; Delay et al. 2012) .
With this in mind, we extended our previous HCS approach to identify miRNAs modulating APP metabolism, and by extension key endogenous factors implicated in APP metabolism. This approach led us to characterize 180 genes targeted by 41 miRNAs. Among these genes, we focused on FERMT2, a known genetic risk factor of sporadic AD (Lambert et al. 2013) .
METHODS

Cell culture
Human HeLa (RRID:CVCL_0030) and HEK293 (RRID:CVCL_0045) cells were respectively maintained in Eagle's minimal essential medium (American Type Culture Collection, Teddington, UK) and DMEM/Ham's F-12 1:1 medium (Life Technologies, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum and 2 mM L-glutamine, penicilline (10 UI/mL)/Streptomycine (10 µg/mL).
High-content miRNA screening
The miRNA library (2,555 miRNA mimics, mirVana™ library, Ambion, Austin, TX) was screened in HEK293 cells stably over-expressing mCherry-APP695 wt -YFP ( Supplementary Fig. 1 ) according to a previous protocol (Chapuis et al. 2017) . Briefly, each miRNA (50 nM) was first transferred to 384well with D-PBS containing 0.1 µl of Lipofectamine RNAiMax (Life Technologies). Then approximately 3,000 HEK293-mCherry-APP695wt-YFP cells were distributed in each well and incubated for 3 d at 37°C. After removal of the cell medium and Hoechst staining, cells were fixed using 10% formalin before image acquisition using an InCell Analyser 6000 (GE Healthcare, Chicago, IL) high-resolution automated confocal microscope.
A customized image analysis software (Columbus 2.7; PerkinElmer, Villebon-sur-Yvette, France) was used for the image analysis and quantification as reported previously (Chapuis et al. 2017) . The mean fluorescence intensity of each signal was normalized with the fold change induced by the nontargeting miRNA in the same plate. To evaluate the impact of each miRNA, an average of 1,000 cells were analyzed per run (n = 3). For quality control, we used strictly standardized mean difference with β-score > 3 based on two separate controls (siRNA-APP and miR-NT, Supplementary Fig. 1 ).
In silico prediction of miRNA targets and functions
Seven publicly-available algorithms were used for the prediction of miRNA-targeted genes in the brain: DIANA-microT-CDS (v5.0, r21) (Paraskevopoulou et al. 2013) , MiRanda (August 2010 release) (John et al. 2004) , mirDB (v5.0) (Wong & Wang 2015) , miRTarBase (v6.1) (Hsu et al. 2011 ), rna22 (v2.0) (Miranda et al. 2006) , TargetMiner (May 2012 release) (Bandyopadhyay & Mitra 2009) , and TargetScan (v7.1) (Agarwal et al. 2015) . In order to minimize false-positive predictions, miRNAtargeted genes were defined as genes predicted by at least 4 out of the 7 algorithms used. To predict the function(s) of miRNAs that target these genes, pathway enrichment analysis was performed using DIANA Tools mirPath (v3.0) (Vlachos et al. 2015) .
Microfluidic chip fabrication
Masters of multi-compartment microfluidic devices were fabricated through photolithography as previously described (Blasiak et al. 2015) . Polydimethylosiloxane (PDMS; Sylgard 184; Dow Corning, Midland, MI) pads were replica molded (2 h at 70°C) and irreversibly bonded to glass coverslips via O 2 plasma (Diener, Ebhausen, Germany). The devices were placed in plastic Petri dishes, UV sterilized for 30 min, and wetted with sterile dH 2 O.
Primary neuronal culture and viral transductions
Primary neuronal cultures were obtained from hippocampus or cortices of post-natal (P0) rats as described previously (Kaech & Banker 2006) . Briefly, after the dissection of the brains, hippocampi were washed three times in HBSS (HBSS, 1 M HEPES, penicilline/streptomycine, 100 mM sodium pyruvate; Gibco) and were dissociated via trypsin digestion (2.5%, 37°C; Gibco) for 7 min. Next, hippocampi were incubated with DNAse (5 mg/mL; Sigma) for 1 min and washed again in MEM medium supplemented with 10% SVF, 1% Glutamax, 0.8% MEM vitamines, 0.5% penicilline/streptomycine and 0.45% D-glucose (Sigma). With a pipette, hippocampi were mechanically dissociated and resuspended in Neurobasal A medium (Gibco) supplemented with 2% B27 (Gibco) and 0.25% GlutaMax. 200,000 neurons were seeded per well in 24-well plates. 50,000 neurons were seeded in the somatic chamber of microfluidic devices, pre-coated with poly-L-lysine (0.1 mg/mL; Sigma) in borate buffer (0.31% boric acid, 0.475% sodium tetraborate, pH = 8.5). 0.1% EDTA (in H 2 O) was added to the Petri dishes containing microfluidic devices to minimize evaporation. The culture medium was refreshed every 3 d. Neurons were maintained at 37°C in a humidified 5% CO 2 incubator.
Lentiviral transductions
Lentiviral transductions were carried out at 1 day in vitro (DIV1) with a multiplicity of infection (MOI) of 10. In the case of co-transduction, MOI of 5 was used for each lentivirus. Briefly, lentiviruses were diluted in culture medium containing 4 µg/mL polybrene (hexadimethrine bromide; Sigma) and were added to the cells. After 6 h of transduction, lentivirus suspension was replaced with fresh medium. The following lentiviruses were used for transduction: Mission shRNA vectors (Sigma) shNT (Non-Mammalian shRNA Control, SHC002), shFERMT2 (TRCN0000191859), shAPP (TRCN0000006707) and pLenti6 empty vectors (Mock) or including human FERMT2 WT or FERMT2 QW cDNA sequences. LifeAct-Ruby lentivirus (pLenti.PGK.LifeAct-Ruby.W: RRID:Addgene_51009) was a kind gift from Rusty Lansford.
Immunoblotting and Aβ quantification
Equal amounts (10-25 µg) of cell lysate were collected in RIPA buffer (1 M Tris, 1.5 M NaCl, 0.1% NP-40, 10% SDS, 100 mM sodium orthovanadate, 0.5% sodium deoxycholate, pH = 7.4) containing protease inhibitors (Complete mini; Roche Applied Science, Penzberg, Germany), lithium dodecyl sulfate (LDS), and reducing agent (Invitrogen). Samples were denaturated and analyzed using SDS-PAGE and the following antibodies: human FERMT2 (RRID:AB_10727911), amyloid precursor protein C-terminal domain (RRID:AB_258409), actin (RRID:AB_476692), β-amyloid clone 6E10
(RRID:AB_662798), β-amyloid clone 4G8 (RRID:AB_662812), Synaptophysin I (RRID:AB_887824), PSD95 (RRID:AB_2619800), GAPDH ( RRID:AB_10615768). Extracellular culture media were collected in order to dose secreted Aβ using Alpha-LISA assays (AlphaLISA Amyloid β 1-X Kit, AL288C, PerkinElmer) according to the manufacturer's instructions.
Cell surface biotinylation
HEK293-APP 695WT cells were transfected with PCDNA4.1, FERMT2 WT or FERMT2 QW (PCDNA4/HisMax, ThermoScientific V86420) for 48 h. Next, cell surface proteins were biotinylated using sulfo-NHS-SS-biotine (sulfosuccinimidyl-20(biotinamido)ethyl-1,3-dithiopropionate) for 30 min at 4°C according to the manufacturer's instructions (Cell Surface Protein Isolation Kit, Pierce, 89881).
Then, cells were lysed and immunoprecipitated with streptavidin beads. Precipitated proteins were eluted from the beads with loading buffer containing 50 mM DTT, heated for 10 min at 95°C and analyzed by WB.
Co-Immunoprecipitation
Equal amounts of protein were collected in co-immunoprecipitation buffer (10 mM HEPES, 140 mM NaCl, 0.5% NP-40, pH = 7.4) containing protease inhibitors (Complete mini, Roche Applied Science) and phosphatase inhibitor (100 mM sodium orthovanadate) and incubated with the primary β-amyloid antibody clone 4G8 (RRID:AB_662812) overnight, with gentle rocking. Production of recombinant C100 fragment was performed as previously described (Sevalle et al. 2009 ). Co-immunoprecipitation was carried out using Pierce Protein A/G magnetic beads kit (Thermo Scientific, 88802) according to the manufacturer's instructions. Samples with proteins and antibody complexes were incubated with 25 µL (0.25 mg) of A/G magnetic beads previously washed with co-immunoprecipitation buffer. After 1 h of incubation at 4°C, the magnetic beads were washed 3×, resuspended with loading buffer (LDS and reducing agent) for 10 min at RT, and analyzed by WB.
Immunofluorescence and PLA
Cells were fixed in 4% paraformaldehyde (PFA) for 15 min, washed 3× with PBS, and permeabilized for 5 min with 0.3% Triton X-100. Cells were incubated with 5% normal donkey serum for 2 h at RT before overnight incubation with the following primary antibodies: human FERMT2
(RRID:AB_10727911), Kindlin2 (RRID:AB_2278298), amyloid precursor protein C-terminal domain (RRID:AB_258409), APP A4 clone 22C11 (RRID:AB_94882), Synaptophysin I ( RRID:AB_887824), PSD95 (RRID:AB_2619800), Homer (RRID:AB_2631222), α-Tubulin (RRID:AB_2210391). The cells were then washed 3× with PBS and incubated with the following secondary antibodies raised in donkey (AlexaFluor-conjugated AffiniPure Fragment 405, 488, 594 or 647, Jackson ImmunoResearch), 1:10,000 Hoechst 33342, or 1/40 SiR-Actin probe (SC001, Spirochrome). Alternatively, Kindlin2 (RRID:AB_2278298) and APP A4 22C11 (RRID:AB_94882) antibodies were used for proximity ligation assay (PLA) according to manufacturer's instructions (Duolink®, Olink Bioscience).
Live-cell microscopy for axon elongation and actin dynamics
After DIV5 
Synaptosome extraction
To verify the presence of proteins at the synaptic level we did a subcellular fractionation as previously described (Frandemiche et al. 2014) . Briefly, cortical neurons were resuspended in a solution (0.32 M sucrose and 10 mM HEPES, pH = 7.4) and were centrifuged at 1,000× g for 10 min to remove nuclei and debris. The supernatant was centrifuged at 12,000× g for 20 min to remove the cytosolic fraction.
The pellet was resuspended in a second solution (4 mM HEPES, 1 mM EDTA, pH = 7.4) and was centrifuged 2× at 12,000× g for 20 min. The new pellet was resuspended in a third solution (20 mM HEPES, 100 mM NaCl, 0.5% Triton X-100, pH = 7.2) for 1 h at 4°C and centrifuged at 12,000× g for 20 min. The supernatant collected corresponds to the non-PSD fraction (Triton-soluble). The remaining pellet was resuspended in a fourth solution (20 mM HEPES, 0.15 mM NaCl, 1% Triton X-100, 1% deoxycholicacid, 1% SDS, pH = 7.5) for 1 h at 4°C and was centrifuged at 10,000× g for 15 min to obtain a supernatant containing the PSD fraction (Triton-insoluble). The different fractions were then analyzed by WB.
Quantification of synaptic connectivity
To quantify synaptic connectivity, we transducted primary hippocampal neurons in pre-and/or postsynaptic compartments of microfludic devices at DIV1 with lentiviruses carrying shNT and/or shFERMT2 (MOI = 10). At DIV14 cultures were fixed and immunostained against Synaptophysin I and Homer pre-and post-synaptic markers, respectively. Synaptic compartments were imaged with Zeiss LSM880 confocal microscope, using a 63× 1.4 NA objective and the AiryScan superresolution unit. Images were analyzed with Imaris software (Bitplane; Zürich, Switzerland) by reconstructing Synaptophysin I and Homer puncta in 3D. The volume and position information of all puncta were processed using a custom Matlab (MathWorks, Natick, MA) program. This program assigns each postsynaptic spot to the nearest presynaptic spot (within a distance threshold of 1 µm) and calculates the number of such assignments for all presynaptic puncta. The percentage of presynaptic spots not assigned by any postsynaptic spot was consistently used as a read-out of synaptic connectivity..
Lentivirus injection
For stereotactic injections, C57Bl6/J mice (RRID:IMSR_JAX:000664) were anesthetized with 4% isoflurane (2 L/min) and placed in a stereotaxic frame (68528, RWD Life Science, Shenzhen, China)
in which the head of the animal was fixed with a pair of ear bars and a perpendicular tooth bar. During surgical procedures 1.5% isoflurane (2 L/min) was delivered through a facial mask via spontaneous respiration. Their body temperature was maintained between 36.5 and 37.5°C with a homeothermic blanket. Head was shaved and Vetedine was applied. Wounds and pressure points were infiltrated with lidocaine. A skin incision was made along the sagittal midline of the scalp. Craniotomy was made to target our structures of interest. Lentiviruses were injected in right and left hippocampus (1.5 µL per hemisphere; 0.2 μL/min). After injections, wound clips were used for skin closure. For the sham group, surgical procedures were performed without any injection. During the surgery, the level of anesthesia was regularly verified by testing the nociceptive hind limb withdrawal reflex. Subjects were then allowed to recover in their home cages for at least 7 d before sacrifice for ex-vivo electrophysiological recordings.
Hippocampal acute slices preparation
One week after the surgery, sagittal hippocampal brain slices were obtained using standard brain slicing methods. Mice were deeply anesthetized with isoflurane and decapitated. The brain was quickly removed and immersed in ice-cold pre-oxygenated artificial cerebrospinal fluid (aCSF) containing: 124 mM NaCl, 3.75 mM KCl, 2 mM MgSO 4 , 2 mM CaCl 2 , 26.5 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 10 mM Glucose, continuously oxygenated (pH = 7,4; 27°C). 350 µm-thick slices were prepared using a Vibratome (VT 1000S; Leica Microsystems, Bannockburn, IL), and placed in a holding chamber filled with aCSF. Slices were allowed to recover in these conditions at least 1 h before recording.
Electrophysiological recordings
For electrophysiological recordings, a single slice was placed in the recording chamber, submerged and continuously superfused with gassed (95% O 2 , 5% CO 2 ) aCSF at a constant rate (2 mL/min).
Extracellular fEPSPs were recorded in the CA1 stratum radiatum using a glass micropipette filled with aCSF. fEPSPs were evoked by the electrical stimulation of Schaffer collaterals/commissural pathway at 0.1 Hz with a glass stimulating electrode placed in the stratum radiatum (100 µsec duration).
To test the effect of miRNA-expressing lentiviruses on basal synaptic transmission, Input/Output (I/V) curves were constructed at the beginning of the experiment. The slope of fEPSPs was measured and plotted against different intensities of stimulation (from 0 to 100 µA).
Stable baseline fEPSPs were recorded by stimulating at 30% maximal field amplitude for 10 min prior to beginning experiments (single stimulation every 10 s (0. 
RFLP genotyping
Genomic DNA in the vicinity of the rs7143400 was amplified by PCR using the following primers 5'-GGTTGGGTGTGAATAGGAAT-3' and 5'-TGCATGCCTGATTTATTTGG-3' before digestion Fig. 4) .
HEK293 clones were isolated by limiting dilution before RFLP genotyping. Sequence integrity of the FERMT2 3'UTR and predicted potential off-target sites were validated by Sanger sequencing (Supplementary Fig. 4 ).
Visualization of miRNA expression at the single-cell level
To visualize RNA molecules by fluorescence at single-cell resolution and quantify gene expression, we used ViewRNA Cell Plus Assay kit (ThermoFischer Scientific) according to the manufacturer's instructions. Briefly, after fixation and permeabilization, cells were washed 3× with PBS containing RNAse inhibitor and were incubated with probes directed against specific mRNA or miRNA for 2 h at 40°C. After washes, probes were amplified, first, in a pre-amplifier solution and secondly, in an amplifier solution, both for 1 h at 40°C. Then, cells were incubated with nucleotide probes stained with different fluorophores allowing the detection of mRNA or miRNA puncta. This approach was coupled with immunofluorescence experiments described. Total RNA was extracted from brain tissue (Supplementary Primers were purchased from ThermoFisher (miR-4504 ID: 464271_mat; RNU48 ID: 001006; miR-222-3p ID: 002276). MiR-4504 and miR-222 levels were normalized to RNU48. The relative amounts of each mature miRNA were calculated using the comparative Ct (2 -ΔΔCt) method (Smith et al. 2011) .
miR quantification in human brain samples
RESULTS
High-content screening and pathway analysis to identify modulators of APP metabolism
We used an unbiased screening approach to identify miRNAs that modulate APP metabolism in our HCS model. This model is based on HEK293 cells stably over-expressing an APP fusion protein (mCherry-APP 695WT -YFP) that allows for the quantification of intracellular APP fragments (Chapuis et al. 2017) . We screened a total of 2,555 mature human miRNAs in a 384-well plate format. As positive control, an siRNA directed against APP was used to calculate the standardized mean difference (denoted as β in Supplementary Fig. 1 ). The complete screen was performed in triplicate and plates with β > 3 were analyzed according to HCS guidelines (Bray et al. 2013 ). This procedure led us to identify 50 miRNAs (top and bottom 1%) with the strongest impact on APP metabolism ( Fig. 1a,   Supplementary Table 1) . Pathway enrichment analysis revealed that these 50 candidate miRNAs are predicted to regulate neuronal pathways such as axon guidance (Fig. 1b) .
To determine which genes were potentially regulated by these top 50 hits, we selected the intersection of predictions resulting from at least four different algorithms (see methods) and thus identified 6,009
putative miRNA-target genes. To further refine the list of predicted genes, we cross-checked them against the 832 genes identified to have a major impact on APP metabolism in our previous genomewide siRNA screen (Fig. 1c) . This resulted in 180 common genes that are putative targets of 41 miRNAs. To determine if any of these 180 genes were preferentially regulated by this pool of 41 miRNAs, we performed 1 million drawing lots of 41 miRNAs among the 2,555 tested and compared them against the list of miRNAs predicted to bind in the 3'-UTR of each of the 180 genes (see Supplementary Fig. 2) . Distribution of the obtained p-values is shown in Fig. 1d . FERMT2 (encoding Kindlin-2), an AD genetic risk factor, was among the 7 most significant genes (p-value < 2.77×10 -4 after Bonferroni correction), i.e., genes that strongly modulate APP metabolism and whose expression are potentially regulated by miRNAs that also strongly modulate APP metabolism. We therefore focused on this gene.
FERMT2/APP interaction is involved in axonal growth
Our pathway analysis highlighted axon guidance as the most enriched pathway in our miRNA screening (Fig. 1b) . APP is already known, to be enriched in axonal growth cones during nervous system development, and acts as a co-receptor for axon guidance and cell migration cues through its interaction with the extracellular matrix (Soldano & Hassan 2014) (Sosa et al. 2013) . We thus investigated the potential involvement of FERMT2 in axonal growth. Using primary neurons cultured in microfluidic devices that fluidically isolate axons from their cell bodies, we first observed the colocalization of endogenous FERMT2 with APP ( Fig. 2a) . We then addressed the impact of FERMT2 silencing on axonal growth cone morphology after transduction with lentiviral vectors expressing either shRNA against FERMT2 (shFERMT2) or a non-targeting shRNA (shNT). Actin staining revealed than FERMT2 under-expression led to a significant decrease in growth cone area (9.13±0.71 vs 12.79±1.10 μm²) as well as in the angular dispersion of growth cone filopodia (0.67±0.04 vs 0.84±0.02) ( Fig. 2b and Supplementary Fig. 3) . Of note, no significant impact on actin retrograde flow rate was observed (0.166±0.003 vs 0.157±0.002 μm/s). These observations suggest a potential impairment of the exploration behavior of the growth cones due to FERMT2 silencing, but not an effect on actin dynamics per se. FERMT2 under-expression was also associated with an accumulation of endogenous APP in the growth cones (1.38±0.11 vs 0.85±0.08, after normalization by the growth cone area).
By performing proximity ligation assay (PLA), we observed PLA spots in axonal growth cones ( Fig.   2a ) suggesting a potential function of the FERMT2/APP complex in axon growth behavior. To address this, we first tested the possibility that APP and FERMT2 form a protein-protein complex via three complementary approaches: (i) Pull-down of endogenous APP from hippocampal primary neuronal culture extracts co-immunoprecipitated endogenous FERMT2 (Fig. 2c) . (ii) Over-expression of wild-type FERMT2 (FERMT2 WT ) was also able to pull-down the recombinant intracellular domain of APP ( Fig. 2d) . (iii) In addition, we generated a Q 621 W 622 AA FERMT2 mutant (FERMT2 QW ) which was previously shown to abolish the interaction between the FERMT2 F3 domain and the NxTY motif of Integrin-β3 (which is also present within the intracellular domain of APP) (Ma et al. 2008 ).
Remarkably, when over-expressed in HEK293 cells, FERMT2 QW was not able to pull-down the recombinant intracellular domain of APP. Cumulatively, these findings support a direct interaction between FERMT2 and APP. Based on the recently solved crystal structure of FERMT2 in complex with the integrin-β3-tail (H. , we built a structural model of the FERMT2/APP complex ( Fig. 2e) , supporting our hypothesis that a protein-protein interaction exists between FERMT2 and APP.
We next assessed the biological impact of the FERMT2/APP interaction on APP metabolism. By performing extracellular biotinylation experiments, we observed that FERMT2 over-expression in HEK293-APP 695wt cell line decreased the levels of APP at the cell surface, an effect that was abolished by the presence of the QW mutation ( Fig. 2f) . Further, a dominant negative effect of the FERMT2 QW mutant was observed: its over-expression impacted APP metabolism similarly to FERMT2 silencing, i.e., resulting in increased mature APP at the cell surface and increased Aβ production, as previously reported (Chapuis et al. 2017) . Altogether, our data suggest that a FERMT2/APP interaction is necessary for FERMT2 to have an impact on APP metabolism.
In order to characterize in-depth the impact of FERMT2 and/or APP expression on axonal growth, we conducted time-lapse microscopy and measured axon growth speed at DIV5 following lentiviral transduction (shNT, shFERMT2, or shAPP) of neurons in microfluidic devices at DIV1. FERMT2 silencing led to 31.7% increase in axon growth speed ( Fig. 3 and Supplementary Fig. 3) . Conversely, APP under-expression led to 16.7% decrease in axon growth speed. Remarkably, silencing of APP was able to fully abolish the effect of FERMT2 under-expression on axon growth speed, suggesting that APP was required for the molecular mechanism by which FERMT2 controls the axon growth speed. In addition, we observed that FERMT2 QW mutant over-expression was able to induce 15.9% increase in axon growth speed (Fig. 3) . Since over-expression of FERMT2 WT did not show any impact, these data also suggested a potential dominant negative effect of the FERMT2 QW mutant and further supported the involvement of FERMT2/APP complex in axonal growth.
FERMT2 is present at the synapse and controls synaptic connectivity
Next, we investigated the impact of FERMT2 silencing on neuronal maturation at DIV14. First, costaining between FERMT2 and synaptic markers (Synaptophysin and Homer) suggested the localization of FERMT2 at the synapse (Fig. 4a) . The presence of FERMT2 in both pre-and postsynaptic compartments was confirmed by synaptosomal purification (Fig. 4b) .
To control shRNA expression separately in pre-or postsynaptic neurons, hippocampal neurons were cultured in microfluidic devices that promote synapse formation in an isolated chamber (Taylor et al. 2010 ).
Thanks to the use of narrow microchannels, these devices spatially isolate neurites from their cell bodies and allow lentiviral transductions to be conducted in different compartments, thereby allowing us to silence FERMT2 expression at the pre-and/or postsynaptic levels ( Fig. 4c and Supplementary   Fig. 3) . The effects of shRNA expression (DIV1) on synaptic connectivity were assessed by confocal microscopy of synaptic markers (DIV14) followed by three-dimensional image segmentation and quantification. Under-expression of FERMT2 in the pre-synaptic chamber led to a decrease in synaptic connectivity, whereas no such effect was observed when under-expressing FERMT2 in the postsynaptic compartment (Fig. 4d) . Altogether, our data suggest that FERMT2 expression is required for synapse connectivity. Moreover, PLA-FERMT2/APP signals were also co-localized with Synaptophysin and Homer puncta (Fig. 4e) supporting the possibility of the involvement of FERMT2/APP complex in synapses.
FERMT2 expression regulates synaptic plasticity in an APP dependent manner
We sought to establish the functional impact of FERMT2 and/or APP silencing on CA1 basal synaptic transmission and long-term potentiation (LTP) in ex vivo mouse hippocampal slices, after stereotactic lentivirus injection allowing expression of shNT, shFERMT2, shAPP or shFERMT2+shAPP. No significant difference was observed for the normalized average slope of the evoked field excitatory postsynaptic potential (fEPSP), indicating no alteration of the CA1 basal synaptic transmission in any of the groups analyzed ( Fig. 5a, Supplementary Fig. 4) . Then, in the same slice, tetanic stimulation was delivered to the Shaffer collaterals (SC) in order to induce LTP (Fig. 5b) . Tetanic stimulation of the SC resulted in a robust, long-lasting potentiation of the fEPSP slope in slices from mice infected with shNT and in shAPP, whereas LTP was impaired in slice from shFERMT2-infected mice. An LTP deficit was observed in hippocampal slices infected with shFERMT2, but not in those infected with shAPP ( Fig. 5c and 5d) . Remarkably, this deficit was abolished when both APP and FERMT2 were silenced, suggesting that APP was required for the molecular mechanism by which FERMT2 impacts LTP.
miR-4504 down-regulates endogenous FERMT2 depending on rs7143400-T allele presence
Altogether, our data indicate that downregulation of FERMT2 have deleterious impacts on several read-outs such as synaptic connectivity and LTP in an APP dependent manner. We previously identified an AD-associated variant (rs7143400), where the minor T allele creates an 8-mer binding site for miR-4504 within the 3'-UTR of FERMT2 (Delay et al. 2016) (Supplementary Fig. 5) . To assess whether miR-4504 was able to modulate endogenous FERMT2, we first generated an rs7143400-mutated HEK293 cell line (HEK293 rs7143400-G/T ) via the CRISPR-Cas9 technology ( Fig. 6a and Supplementary Fig. 6) . Transfection of miR-4504 led to a decrease in FERMT2 expression only in the HEK293 rs7143400-G/T cell line and not in the wild-type HEK293 (HEK293 rs7143400-GG ). Notably, miR-4504 was also able to down-regulate endogenous FERMT2 expression in HeLa cells that are heterozygous for rs7143400 ( Fig. 6b) . We then addressed the possibility that miR-4504 modulates APP metabolism through a direct down-regulation of FERMT2. We observed that miR-4504 transfection was associated with an increase in total APP in both cell lines carrying the rs7143400-T allele (Fig. 6b) . Our findings indicate that miR-4504 have the same impact on APP metabolism as seen by FERMT2 silencing alone, i.e., an increase in total APP (Chapuis et al. 2017 ).
To provide further physiological relevance to our findings, we combined classical immunocytochemistry with RNA hybridization allowing miRNA detection at single-copy sensitivity.
We first observed that miR-4504 was almost exclusively expressed in neurons in our primary hippocampal cultures (Fig. 6c) . We next measured the expression levels of miR-4504 in the postmortem brain samples from 52 AD patients and 30 control subjects. We observed that the expression level of miR-4504 was significantly increased in AD brains compared to controls (Fig. 6d) . Taken together, these data suggest that miR-4504 is able to down-regulate endogenous FERMT2 expression and to modulate APP metabolism. In addition, this miRNA-dependent regulation is depends on a functional genetic variant associated with an increased AD risk. This implies that under-expression of FERMT2 in neurons may be potentially deleterious in the pathophysiological context of AD (Fig. 6e) .
Discussion
As in other multifactorial diseases, GWAS in AD are agnostic approaches, and how a genetic risk factor is implicated in pathophysiological processes is typically unknown. Sometimes, even the physiological functions of an AD genetic risk factor in the brain are not known. Understanding the role of these genes is thus a challenge that requires several key questions to be addressed: (i) Does the corresponding protein interact (directly or indirectly) with other key players and pathways known to be involved in AD? (ii) What is (are) the functional variant(s) responsible for the GWAS signal and does this (do these) variant(s) impact the biological function of the corresponding protein and its interaction with key players of AD?
To answer these questions, we developed systematic approaches to determine the genes that are involved in APP metabolism, a major player in AD development. To this end, we had previously developed an HCS, based on the quantification of intracellular APP fragments, to measure the impact of under-expression of 18,107 genes (via siRNA pools) on APP metabolism (Chapuis et al. 2017 ). In the current study, we screened the impact of the over-expression of 2,555 miRNAs on APP metabolism with the hypothesis that genes (i) that modulate the APP metabolism and (ii) whose expression levels are regulated by miRNAs that also modulate the APP metabolism are likely some of the key actors controlling the APP metabolism and functions. The convergence of these two agnostic screens highlighted FERMT2, a GWAS-defined genetic risk factor of AD, for which almost nothing is known in the cerebral and AD contexts. We demonstrate that a direct interaction between FERMT2
and APP -through the F3 domain of FERMT2 and the NxTY motif within APP's intracellular domain-is necessary for FERMT2 to have an impact on APP metabolism. Moreover, we observed that the FERMT2/APP interaction could be involved in the regulation of axonal growth, in line with APP's function within the growth cone (Sosa et al. 2013 ) (data we replicated in this study). It has been reported that FERMT2 is required for the recruitment and activation of focal adhesion kinase and the triggering of integrin signaling (Theodosiou et al. 2016) . In neuron, focal adhesion is involved in synaptic density and activity through spine shape, stability and signalling machinery therein (Hotulainen & Hoogenraad 2010) . Interestingly, our data suggest that FERMT2 expression, particularly in pre-synaptic compartment might participate to synaptic connectivity. Apart from this developmental read-out, we also analyzed synaptic plasticity, a read-out more relevant to AD, where synaptic dysfunction/loss is one of the earliest events observed. FERMT2 under-expression leads to a harmful effect on LTP in an APP-dependent manner. As FERMT2 silencing leads to an accumulation of full-length APP and all by-products (including Aβ peptides), we can hypothesize that these accumulations could be involved in the synaptic dysfunction observed when FERMT2 is underexpressedalthough further experiments are needed to decipher the potential causal link between FERMT2 and APP, i.e., to determine whether it impacts the function of full-length APP or invokes Aβ synaptotoxicity. This is of particular interest, since APP shedding strongly enhances its cell adhesion and synaptogenic activity (Stahl et al. 2014) . Moreover, the APP intracellular domain is required for normal synaptic morphology and synaptic plasticity, suggesting that intracellular interactors could be required for proper synaptic function (Klevanski et al. 2015) . Remarkably, we have recently proposed a circular model of AD pathogenesis, where the core of the focal adhesion pathway -which FERMT2
and APP are part of-may participate in the dysfunction of synaptic plasticity in AD (Dourlen et al. 2019 ).
In addition, we previously identified the rs7143400 variant located in FERMT2 3'UTR to be susceptible to alter a binding site for miR-4504 (Delay et al. 2016) . Here, in addition to in silico prediction suggesting the impact of this variant on miRNA binding (Supplementary Fig. 5) , we demonstrate that this variant is functional: the AD-associated rs7143400 T allele down-regulates FERMT2 and modulates APP metabolism via its interaction with miR-4504. Remarkably, we observed that miR-4504 is over-expressed in the brains of AD cases compared to controls, and is mainly expressed in neurons in primary mixed hippocampal cultures.
Together, our data indicate that a deleterious over-expression of miR-4504 can lead to a decrease in FERMT2 expression in individuals bearing the rs7143400 minor T allele, which subsequently modulates APP metabolism (Fig. 6e) . Supporting a link between FERMT2 and APP metabolism, studies from cohorts of patients have reported an association between variants in FERMT2 gene and Aβ in CSF (Chapuis et al. 2017 ) and brain amyloidosis (Apostolova et al. 2018 ).
Of note, in publicly-available RNA-seq analyses (Mayo Clinic Brain Bank), an over-expression of FERMT2 mRNA is observed in post-mortem human temporal cortex of AD patients relative to controls (Sullivan et al. 2018) . Even if we did not observe such a variation of the FERMT2 mRNA level in a smaller number of brains, we nevertheless detected an increase in the protein levels as a function of Braak stage, especially at later stages (Supplementary Fig. 7) . This point is of particular importance since in the Genotype-Tissue Expression Database (GTEx Consortium et al. 2015) , FERMT2 variants associated with an increase in AD risk at the genome-wide significance level are also part of an expression quantitative trait locus, significantly associated with decreased brain expression of FERMT2 mRNA (sentinel variant in GWAS rs17125924; -18%; p-value = 2×10 -6 ). This observation strongly supports our conclusion that FERMT2 under-expression is deleterious and suggests that FERMT2 down-regulation would be deleterious at the earliest stage of the disease, whereas, FERMT2 over-expression may occur as a pathological consequence at a very late stage.
Here, we propose that FERMT2 down-regulation at the earliest stage of AD would depend in part on (i) the miR-4504 expression, (ii) cerebral cell type (i.e., neurons), and (iii) the presence of the rs7143400 minor T allele (observed in 9% of Caucasians). Unfortunately, it is important to keep in mind that all these constraints will make difficult, if not impossible, to detect such a miRNAdependent decrease in FERMT2 mRNA levels. Of note, this point may also underline the limitation of expression databases in deciphering the mechanisms underlying the functional effects of GWAS variants, for they do not allow capturing (even hide) subtle mechanisms.
In conclusion, we propose that FERMT2 under-expression through miRNAs and/or genetic regulation leads to synaptic dysfunction in an APP-dependent manner. Our hypothesis may thus call for new therapeutic approaches in AD targeting FERMT2 and/or APP function, rather than Aβ peptide production/clearance. Once therapeutic approaches that target FERMT2-dependent pathways are eventually developed, one can argue that it might be an example of personalized medicine for AD, preferentially targeting patients who have high levels of miR-4504 and who bear the rs7143400 minor T allele. 
c.
A graphical representation of the workflow developed to identify miRNA-targeted genes that are also able to modulate APP metabolism according to our previous genome-wide, high-content siRNA screening. Predictions of target sites for genes expressed in the brain were determined by at least 4 out of 7 software programs used (see methods). d. p-value distribution for the 180 genes targeted by the 41 miRNAs identified by HCS (also see Fig. S2 ). In red, genes significantly enriched to be targeted by these 41 miRNAs after Bonferroni correction (0.05 / 180 = 2.77×10 -4 ) including FERMT2, a genetic risk factor of AD. 
